Evidence map›Paper›PMID 41158238›Full record

ArticleTranslational cancer research2025

Haiyan Wang, Jianhui Liu, Xiaoying A, Jialiang Wang, Qingfen Mu, Anqi Yang, Jing Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Research progress ofFrontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haiyan WangDepartment of Gynecology, Affiliated Hospital of Qinghai University, Xining, China.
Jianhui LiuDepartment of Gynecology, Affiliated Hospital of Qinghai University, Xining, China.
Xiaoying ADepartment of Gynecology, Affiliated Hospital of Qinghai University, Xining, China.
Jialiang WangDepartment of Gynecology, Affiliated Hospital of Qinghai University, Xining, China.
Qingfen MuDepartment of Gynecology, Affiliated Hospital of Qinghai University, Xining, China.
Anqi YangDepartment of Gynecology, Affiliated Hospital of Qinghai University, Xining, China.
Jing ZhouDepartment of Gynecology, Affiliated Hospital of Qinghai University, Xining, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: CMTM4 is involved in various cellular processes, such as cancer progression and immune regulation. However, its precise role in cervical cancer remains unclear. This study aimed to investigate the impact of CMTM4 on HeLa cell behavior, tumorigenesis, myeloid-derived suppressor cell (MDSC) generation, and immunosuppressive effects in the context of cervical cancer. Methods: HeLa cells were genetically engineered to overexpress Results: Immunohistochemical and Western blot analyses indicated a diminished expression of the CMTM4 protein in cervical cancer tissues relative to adjacent non-cancerous tissues. Conclusions: CMTM4 emerges as a critical regulator in cervical cancer, influencing both tumor cell behavior and the immune microenvironment.

Indexed as

AKT/STAT3/ERK signaling pathwayCervical cancerCMTM4myeloid-derived suppressor cells (MDSCs)

Identifiers

PMID41158238
PMCPMC12554492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.